



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imclshares@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Ref: IMCL/CS/BM/2026

3rd February, 2026

The Manager
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai, (Maharashtra) - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, (Maharashtra) - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 3rd February, 2026

Dear Sir,

Pursuant to Regulation 30, and 33 read with Schedule III of the SEBI Listing Regulations, 2015, this is to inform that the Board of Directors of the Company has, at its meeting held on Tuesday, 3rd February 2026 (i.e., today), inter-alia, considered and approved the following items:

1. Considered and approved the Un-audited Financial Results of the Company for the quarter and nine months ended 31st December 2025.

Considered and approved the Un-audited Financial Results for the quarter and nine months ended 31st December, 2025, along with the Limited Review Report of the Statutory Auditors.

We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2025, along with a copy of the Limited Review Report by the Statutory Auditors of the Company – **Annexure 1**.

The above said documents are being posted on the website of the Company i.e., <https://www.apollohospitals.com/delhi>.

The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

2. Noted additional Affidavit filed by Govt. of NCT of Delhi in the pending Free Patient Matter i.e., SLP (C) No. 29482/2009.

This is to inform that an affidavit has been filed by the Government of NCT of Delhi before the Hon'ble Supreme Court of India in relation to the proceedings concerning the lease of land on which the Company's hospital at Sarita Vihar is situated.



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imclshares@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



The affidavit forms part of the record of the ongoing proceedings. The matter is presently under consideration of the Hon'ble Supreme Court.

The Company is reviewing the contents of the affidavit and will take such steps as may be considered appropriate in accordance with law. Further disclosures, if any, will be made in accordance with applicable regulatory requirements.

3. Appointed Mr. Harsh Pati Singhania (00086742) as an Independent Director

Pursuant to the provisions of Section 149 and Section 161 of the Companies Act, 2013 and Regulation 16, 17 & 25 of the SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have appointed Mr. Harsh Pati Singhania (DIN 00086742) as an Additional Director, in the capacity of "Non-Executive Independent Director" of the Company, for a period of 5 consecutive years effective from 3rd February, 2026 to 2nd February, 2031, subject to the approval of Shareholders of the company.

Mr. Harsh Pati Singhania is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, is not disqualified to be appointed as an Independent Director.

The details as required under Regulation 30 of Listing Obligations, read with the relevant Circular issued thereunder are provided in the enclosed **Annexure - 2**.

4. Re-appointed Mr. Salil Singhal (DIN 00006629) as an Independent Director

Pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have re-appointed Mr. Salil Singhal (DIN 00006629) as an Independent Director, for a period of 5 consecutive years, effective from 8th February 2026 to 7th February 2031, subject to approval of shareholders of the Company by way of Special Resolution.

The details as required under Regulation 30 of Listing Obligations, read with the relevant Circular issued thereunder are provided in the enclosed **Annexure - 3**.

5. Re-Appointed Ms. Vineeta Rai (DIN 07013113) as an Independent Director

Pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have re-appointed Ms. Vineeta Rai (DIN 07013113) as an Independent



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imclshares@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Director, for a period of 5 consecutive years, effective from 8th February, 2026 to 7th February, 2031, subject to approval of shareholders of the Company by way of Special Resolution.

The details as required under Regulation 30 of Listing Obligations, read with the relevant Circular issued thereunder are provided in the enclosed **Annexure - 4**.

6. Re-Appointed Ms. Madhumita Ganguli (DIN 00676830) as an Independent Director

Pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have re-appointed Ms. Madhumita Ganguli (DIN 00676830) as an Independent Director, for a period of 5 consecutive years, effective from 9th June, 2026 to 8th June 2031, subject to approval of shareholders of the Company by way of Special Resolution.

The details as required under Regulation 30 of Listing Obligations, read with the relevant Circular issued thereunder are provided in the enclosed **Annexure - 5**.

The Board meeting commenced at 3.00 p.m. and ended at 05:10 p.m.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited

Priya Ranjan
AVP – Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Encl.: As above

S N Dhawan & CO LLP
Chartered Accountants

51-52, IInd Floor, Sector 18, Phase-IV,
Udyog Vihar, Gurugram,
Haryana 122015, India
Tel.: +91 124 481 4444

Review Report on Unaudited Financial Results

To the Board of Directors of Indraprastha Medical Corporation Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended 31 December 2025 and the year to date results for the period from 01 April 2025 to 31 December 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34') prescribed under Section 133 of the Companies Act, 2013 ("the Act"), other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S N Dhawan & CO LLP**
Chartered Accountants
Firm Registration No.: 000050N/N500045

B. Sen.

Bhaskar Sen
Partner
Membership No.: 096985
UDIN: 26096985FOELGK3581



Place: New Delhi
Date: 03 February 2026


Statement of Unaudited Financial Results for the Quarter and Nine-months ended 31st December, 2025

S. No.	Particulars	Quarter ended			Period ended		Year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	371.61	381.03	324.93	1117.70	1022.61	1356.36
2	Other income	7.15	7.37	5.13	21.42	16.30	22.65
3	Total income	378.76	388.40	330.06	1139.12	1038.91	1379.01
4	Expenses						
	a) Cost of materials consumed	63.75	65.45	56.18	192.04	171.34	230.46
	b) Employee benefits expense	74.89	73.58	72.18	213.42	210.38	277.10
	c) Professional charges to doctors	95.46	99.50	86.04	292.80	267.87	355.18
	d) Finance costs	1.46	1.51	1.58	4.53	4.78	6.27
	e) Depreciation and amortisation expense	11.25	10.86	11.21	32.29	33.42	44.33
	f) Other expenses	75.56	71.19	58.34	213.03	190.07	249.35
	Total expenses	322.37	322.09	285.53	948.11	877.86	1162.69
5	Profit before exceptional items and tax	56.39	66.31	44.53	191.01	161.05	216.32
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (PBT)	56.39	66.31	44.53	191.01	161.05	216.32
8	Tax expense						
	Current tax	12.56	16.36	11.87	46.35	42.28	59.38
	Deferred tax	2.83	0.49	(0.15)	2.74	(1.21)	(4.05)
9	Profit for the period after tax (PAT)	41.00	49.46	32.81	141.92	119.98	160.99
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	0.60	(3.30)	(0.15)	3.28	0.89	(1.10)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.15)	0.83	0.04	(0.82)	(0.22)	0.28
	Total other comprehensive income (Net of tax expenses)	0.45	(2.47)	(0.11)	2.46	0.67	(0.82)
11	Total comprehensive income for the period	41.45	46.99	32.70	144.38	120.65	160.17
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year						505.01
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	4.47	5.40	3.58	15.48	13.09	17.56

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 3rd February, 2026.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of Companies Act, 2013 ("the Act"), read with relevant rules there under and in terms of Regulation 33 of the SEBI (listing obligations and disclosure requirements) Regulations, 2015 (as amended).
- The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz. Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes have been made effective from 21st November, 2025. The Company has accounted for incremental estimated liability amounting to Rs. 2.87 crores in the Statement of Unaudited Financial Results during the current quarter.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Company does not have any subsidiary/associate/joint venture company(ies), as on 31st December, 2025.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : Chennai
Date : 3rd February, 2026


Shivakumar Pattabhiraman
(Managing Director)
DIN: 08570283

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

S. No.	Particulars	Mr. Harsh Pati Singhania (DIN 00086742)
1	Reason for change (Appointment)	The Board of Directors have, based on the recommendation of Nomination and Remuneration Committee, appointed Mr. Harsh Pati Singhania (DIN 00086742) as an Additional Director in the category of Non-Executive Independent Director, subject to the approval of the shareholders.
2	Date of Appointment	3 rd February, 2026
3	Term of Appointment	For a period of 5 years starting from 3 rd February, 2026 to 2 nd February, 2031.
3	Brief Profile	<p>Mr. Harsh Pati Singhania is a MBA from University of Massachusetts and alumnus of Harvard Business School, USA, belongs to one of India's largest industrial groups - J.K. Organisation which operates in diverse businesses like Paper, Cement, Tyres, Auto Engineering, Hybrid Seeds, Dairy/Food, Defence, Textiles etc. having a turnover of around USD 6.0 billion. Shri Singhania is Chairman & Managing Director of JK Paper Ltd., one of the leading companies of the Group.</p> <p>He is currently a First Vice-Chair and Member of Executive Board of International Chamber of Commerce (ICC), Paris which is the apex body for all Chambers of Commerce globally. He also serves as a Member on the Board of Governors of International Management Institute (IMI), Board of Management of JK Lakshmipat University (JKLU) and Pushpawati Singhania Hospital & Research Institute (PSRI).</p> <p>He is a Non-Executive Independent Director in Graphite India Limited and Non-Executive Non-Independent Director in J.K. Fenner (India) Limited, Anant Design Private Limited, Rockwood Properties Private Limited, Oakwood Properties & Farms Private Limited, Horizon Packs Private Limited, Securipax Packaging Private Limited, Pushpawati Singhania Hospital & Research Institute.</p>

4	Disclosure of relationships between the Directors	Mr. Harsh Pati Singhania is not related to any Directors of the Company.
5	Information as required under Circular no. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated 20 th June, 2018, issued by the BSE and NSE, respectively	Mr. Harsh Pati Singhania is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, is not disqualified to be appointed as an Independent Director.

Annexure 3

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

S. No.	Particulars	Mr. Salil Singhal (DIN 00006629)
1	Reason for change (Re-Appointment)	The Board of directors have, based on the recommendation of Nomination and Remuneration Committee, re-appointed Mr. Salil Singhal (DIN 00006629) as an Independent Director of the Company for a second term of 5 consecutive years with effect from 8 th February 2026 to 7 th February 2031, subject to approval of the shareholders by way of Special Resolution.
2	Date of Appointment	3 rd February 2026
3	Term of Appointment	For a period of 5 years starting 8 th February 2026 to 7 th February 2031
3	Brief Profile	<p>Mr. Salil Singhal is a B.A. (Hons.) graduate in Political Science from St. Xavier's College, Mumbai, and is widely recognized as an eminent industry leader with over five decades of distinguished experience. Associated with Indian industry since 1965, he brings deep expertise in corporate leadership, governance, risk management, diversity and strategic business development. His background and long-standing industry engagement continues to provide the Board with valuable perspective and strategic depth, consistent with the expectations for Independent Directors in leading listed companies.</p> <p>Mr. Singhal serves as the Chairman Emeritus of PI Industries Ltd. and has played a pivotal role in the growth, transformation and globalisation of businesses across agrochemicals, fine chemicals, electronic metering services and solutions, and mining and mineral processing. He is particularly known for his strong marketing and business development acumen, which has contributed to building internationally competitive organisations with a forward-looking outlook and a focus on research, development and technological advancement.</p>

		During his tenure as an Independent Director of the Company, Mr. Singhal has contributed through his strategic insights, long-range vision, business understanding and governance experience. He is widely regarded as a professional of high calibre and integrity, bringing depth, maturity and seasoned judgment to the Board.
4	Disclosure of relationships between the Directors	Mr. Salil Singhal is not related to any Directors of the Company.
5	Information as required under Circular no. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated 20 th June, 2018, issued by the BSE and NSE, respectively	Mr. Salil Singhal is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, is not disqualified to be appointed as an Independent Director.

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

S. No.	Particulars	Ms. Vineeta Rai (DIN: 07013113)
1	Reason for change (Re-Appointment)	The Board of directors have, based on the recommendation of Nomination and Remuneration Committee, re-appointed Ms. Vineeta Rai (DIN: 07013113) as an Independent Director of the Company for a second term of 5 consecutive years with effect from 8 th February 2026 to 7 th February 2031, subject to approval of the shareholders by way of Special Resolution.
2	Date of Appointment	3 rd February 2026
3	Term of Appointment	For a period of 5 years starting 8 th February 2026 to 7 th February 2031
3	Brief Profile	<p>Ms. Vineeta Rai, IAS (Retd., 1968 batch, AGMUT cadre), is a distinguished public administrator with extensive experience across health administration, finance, regulatory governance and public policy. She holds a B.A. (Hons.) degree from Delhi University, a B.A. in American History and Politics from Brandeis University, USA, and was a Visiting Fellow in Public Administration at Queen Elizabeth House, Oxford University, UK.</p> <p>Over the course of her career with the Government of India, she has held several senior leadership positions, including in the Ministry of Health & Family Welfare and as Secretary, Banking, Insurance and Revenue in the Ministry of Finance, contributing significantly to policy formulation, institutional strengthening and sectoral reforms in key national domains. business understanding and governance experience. He is widely regarded as a professional of high calibre and integrity, bringing depth, maturity and seasoned judgment to the Board.</p> <p>The Board's evaluation confirms that Ms. Rai continues to demonstrate exemplary integrity, sound judgment and independence of thought. Her balanced approach, ability to analyse complex matters, and constructive guidance, particularly in areas relating to governance, compliance and public policy have significantly enhanced the</p>

		<p>quality and depth of the Board's discussions since 2014. Her extensive administrative experience enables her to assess governance and risk matters with clarity, rigour and perspective.</p> <p>Known for her integrity, sound judgment and deep policy insight, Ms. Rai brings substantial value through her extensive administrative experience and strong understanding of governance and regulatory systems. Her multifaceted expertise makes her a respected figure across public administration and corporate governance circles.</p>
4	Disclosure of relationships between the Directors	Ms. Vineeta Rai is not related to any Directors of the Company.
5	Information as required under Circular no. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated 20 th June, 2018, issued by the BSE and NSE, respectively	Ms. Vineeta Rai is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, is not disqualified to be appointed as an Independent Director.

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

S. No.	Particulars	Ms. Madhumita Ganguli (DIN: 00676830)
1	Reason for change (Re-Appointment)	The Board of directors have, based on the recommendation of Nomination and Remuneration Committee, re-appointed Ms. Madhumita Ganguli (DIN 00676830) as an Independent Director of the Company for a second term of 5 consecutive years with effect from 9 th June 2026 to 8 th June 2031, subject to approval of the shareholders by way of Special Resolution.
2	Date of Appointment	3 rd February 2026
3	Term of Appointment	For a period of 5 years starting 9 th June 2026 to 8 th June 2031.
3	Brief Profile	<p>Ms. Madhumita Ganguli, LL.B., is a seasoned legal and housing finance professional and a member of the Executive Management of HDFC Ltd., one of India's largest mortgage lenders. With over 38 years of extensive experience spanning legal affairs, business operations, housing finance, and real estate, she brings deep institutional knowledge and sound professional judgment to the Board.</p> <p>During the evaluation period, Ms. Ganguli demonstrated strong leadership, governance acumen, and a high degree of diligence in overseeing critical Board Committees. Her effective stewardship of the Audit, Risk, Fraud, and Complaints Committee on Sexual Harassment reflects her commitment to robust internal controls, ethical standards, regulatory compliance, and risk mitigation. She actively contributes to Board deliberations with well-reasoned legal and strategic insights, thereby enhancing the overall effectiveness and governance standards of the Board.</p> <p>The Board's evaluation confirms that Ms. Ganguli continues to demonstrate exemplary integrity, sound judgment and independence of thought. Her balanced approach, ability to analyse complex matters, and constructive guidance, particularly in areas relating to Audit, risk and fraud have significantly enhanced the quality and depth of the</p>

		Board's discussions quality and depth of the Board's discussions
4	Disclosure of relationships between the Directors	Ms. Madhumita Ganguli is not related to any Directors of the Company.
5	Information as required under Circular no. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated 20 th June, 2018, issued by the BSE and NSE, respectively	Ms. Madhumita Ganguli is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, is not disqualified to be appointed as an Independent Director.